Dopamine and pain sensitivity: Neither sulpiride nor acute phenylalanine and tyrosine depletion have effects on thermal pain sensations in healthy volunteers

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Becker, Susanne ^a,b   Ceko, Marta ^c   Louis Foster, Mytsumi ^a   Elfassy, Nathaniel M ^a   Leyton, Marco ^d,e,f   Shir, Yoram ^g   Schweinhardt, Petra ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f NONE   (Canada)

^g MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; PHENYLALANINE; PROLACTIN; SULPIRIDE; TYROSINE;

ADULT; ANTINOCICEPTION; ARTICLE; AVERSION; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NOCICEPTION; NORMAL HUMAN; PAIN THRESHOLD; PROTEIN DEPLETION; REWARD; STIMULUS RESPONSE; SYNAPTIC MEMBRANE; TEMPERATURE SENSE; TEMPORAL SUMMATION; VOLUNTEER; YOUNG ADULT;

ADOLESCENT; ADULT; AFFECT; ANXIETY; DOPAMINE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; PAIN; PAIN PERCEPTION; PAIN THRESHOLD; PHENYLALANINE; PRESYNAPTIC TERMINALS; RECEPTORS, DOPAMINE D2; SULPIRIDE; THERMOSENSING; TYROSINE; YOUNG ADULT;

EID: 84893173947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0080766     Document Type: Article

References (93)

1. Berridge KC, Robinson TE, Aldridge JW (2009) Dissecting components of reward: 'liking', "wanting," and learning. Curr Opin Pharmacol 9: 65-73. doi:10.1016/j.coph.2008.12.014. PubMed: 19162544.
2. Salamone JD, Correa M (2012) The mysterious motivational functions of mesolimbic dopamine. Neuron 76: 470-485. doi:10.1016/j.neuron.2012.10.021. PubMed: 23141060.
3. Jarcho JM, Mayer EA, Jiang ZK, Feier NA, London ED (2012) Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction. Pain 153: 744-754. doi:10.1016/j.pain.2012.01.002. PubMed: 22386471.
4. Potvin S, Grignon S, Marchand S (2009) Human evidence of a supraspinal modulating role of dopamine on pain perception. Synapse 63: 390-402. doi:10.1002/syn.20616. PubMed: 19173266.
5. Wood PB (2008) Role of central dopamine in pain and analgesia. Expert Rev Neurother 8: 781-797. doi:10.1586/14737175.8.5.781. PubMed: 18457535.
6. Hagelberg N, Jääskeläinen SK, Martikainen IK, Mansikka H, Forssell H et al. (2004) Striatal dopamine D2 receptors in modulation of pain in humans: a review. Eur J Pharmacol 500: 187-192. doi:10.1016/j.ejphar.2004.07. 024. PubMed: 15464032.
7. Leknes S, Tracey I (2008) A common neurobiology for pain and pleasure. Nat Rev Neurosci 9: 314-320. doi:10.1038/nrn2333. PubMed: 18354400.
8. Shimizu T, Iwata S, Morioka H, Masuyama T, Fukuda T et al. (2004) Antinociceptive mechanism of L-DOPA. Pain 110: 246-249. doi:10.1016/j.pain.2004. 03.038. PubMed: 15275774.
9. Barasi S, Ben-Sreti MM, Clatworthy AL, Duggal KN, Gonzalez JP et al. (1987) Dopamine receptor-mediated spinal antinociception in the normal and haloperidol pretreated rat: effects of sulpiride and SCH 23390. Br J Pharmacol 90: 15-22. doi:10.1111/j.1476-5381.1987.tb16820.x. PubMed: 3545350.
10. Magnusson JE, Fisher K (2000) The involvement of dopamine in nociception: the role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res 855: 260-266. doi:10.1016/S0006-8993(99)02396-3. PubMed: 10677598.
11. Altier N, Stewart J (1999) The role of dopamine in the nucleus accumbens in analgesia. Life Sci 65: 2269-2287. doi:10.1016/S0024-3205(99)00298-2. PubMed: 10597883.
12. Ansah OB, Leite-Almeida H, Wei H, Pertovaara A (2007) Striatal dopamine D2 receptors attenuate neuropathic hypersensitivity in the rat. Exp Neurol 205: 536-546. doi:10.1016/j.expneurol.2007.03.010. PubMed: 17451685.
13. Clarke PB, Franklin KB (1992) Infusions of 6-hydroxydopamine into the nucleus accumbens abolish the analgesic effect of amphetamine but not of morphine in the formalin test. Brain Res 580: 106-110. doi:10.1016/0006-8993(92) 90932-Y. PubMed: 1504789.
14. Saadé NE, Atweh SF, Bahuth NB, Jabbur SJ (1997) Augmentation of nociceptive reflexes and chronic deafferentation pain by chemical lesions of either dopaminergic terminals or midbrain dopaminergic neurons. Brain Res 751: 1-12. doi:10.1016/S0006-8993(96)01164-X. PubMed: 9098562.
15. Fleetwood-Walker SM, Hope PJ, Mitchell R (1988) Antinociceptive actions of descending dopaminergic tracts on cat and rat dorsal horn somatosensory neurones. J Physiol 399: 335-348. PubMed: 2841456.
16. Gear RW, Aley KO, Levine JD (1999) Pain-induced analgesia mediated by mesolimbic reward circuits. J Neurosci 19: 7175-7181. PubMed: 10436070.
17. Lapirot O, Melin C, Modolo A, Nicolas C, Messaoudi Y et al. (2011) Tonic and phasic descending dopaminergic controls of nociceptive transmission in the medullary dorsal horn. Pain 152: 1821-1831. doi: 10.1016/j.pain.2011.03.030. PubMed: 21514054.
18. Taniguchi W, Nakatsuka T, Miyazaki N, Yamada H, Takeda D et al. (2011) In vivo patch-clamp analysis of dopaminergic antinociceptive actions on substantia gelatinosa neurons in the spinal cord. Pain 152: 95-105. doi:10.1016/j.pain. 2010.09.034. PubMed: 21050660.
19. Ertas M, Sagduyu A, Arac N, Uludag B, Ertekin C (1998) Use of levodopa to relieve pain from painful symmetrical diabetic polyneuropathy. Pain 75: 257-259. doi:10.1016/S0304-3959(98)00003-7. PubMed: 9583761.
20. Dickey RP, Minton JP (1972) Levodopa relief of bone pain from breast cancer. N Engl J Med 286: 843. doi:10.1056/NEJM197204132861518. PubMed: 5011796.
21. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H et al. (2007) Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 25: 3576-3582. doi:10.1111/j.1460-9568.2007.05623.x. PubMed: 17610577.
22. Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T et al. (2003) Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 101: 149-154. doi:10.1016/S0304-3959(02)00323-8. PubMed: 12507709.
23. Hagelberg N, Forssell H, Aalto S, Rinne JO, Scheinin H et al. (2003) Altered dopamine D2 receptor binding in atypical facial pain. Pain 106: 43-48. doi:10.1016/S0304-3959(03)00275-6. PubMed: 14581109.
24. Nandhagopal R, Troiano AR, Mak E, Schulzer M, Bushnell MC et al. (2010) Response to heat pain stimulation in idiopathic Parkinson's disease. Pain Med 11: 834-840. doi:10.1111/j.1526-4637.2010.00866.x. PubMed: 20624238.
25. Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T et al. (2007) Levodopa raises objective pain threshold in Parkinson's disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 78: 1140-1142. doi:10.1136/jnnp.2007.120212. PubMed: 17504881.
26. Treister R, Pud D, Ebstein RP, Laiba E, Gershon E et al. (2009) Associations between polymorphisms in dopamine neurotransmitter pathway genes and pain response in healthy humans. Pain 147: 187-193. doi:10.1016/j.pain.2009. 09.001. PubMed: 19796878.
27. Cevoli S, Mochi M, Scapoli C, Marzocchi N, Pierangeli G et al. (2006) A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol 13: 1009-1013. doi:10.1111/j.1468-1331. 2006.01415.x. PubMed: 16930369.
28. Treister R, Pud D, Ebstein RP, Eisenberg E (2013) Dopamine transporter genotype dependent effects of apomorphine on cold pain tolerance in healthy volunteers. PLOS ONE 8: e63808. doi:10.1371/journal.pone.0063808. PubMed: 23704939.
29. Treister R, Pud D, Eisenberg E (2013) The Dopamine Agonist Apomorphine Enhances Conditioned Pain Modulation in Healthy Humans. Neurosci Lett 548: 115-119. doi:10.1016/j.neulet.2013.05.041. PubMed: 23727387.
30. Kendler KS, Bracha HS, Davis KL (1982) Dopamine autoreceptor and postsynaptic receptor blocking potency of neuroleptics. Eur J Pharmacol 79: 217-223. doi:10.1016/0014-2999(82)90627-6. PubMed: 6124428.
31. Costall B, Fortune DH, Hui SC, Naylor RJ (1980) Neuroleptic antagonism of the motor inhibitory effects of apomorphine within the nucleus accumbens: drug interaction at presynaptic receptors? Eur J Pharmacol 63: 347-358. doi:10.1016/0014-2999(80)90265-4. PubMed: 6104603.
32. Kuroki T, Meltzer HY, Ichikawa J (1999) Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288: 774-781. PubMed: 9918588.
33. Standish-Barry HM, Bouras N, Bridges PK (1983) A randomized double blind group comparative study of sulpiride and amitriptyline in affective disorder. Psychopharmacology 81(3): 258-260. doi:10.1007/BF00427274. PubMed: 6417717.
34. O'connor SE, Brown RA (1982) The pharmacology of sulpiride - a dopamine receptor antagonist. Gen Pharmacol Vasc Syst 13(3): 185-193. doi:10.1016/0306-3623(82)90088-X.
35. Villemure C, Slotnick BM, Bushnell MC (2003) Effects of odors on pain perception: deciphering the roles of emotion and attention. Pain 106: 101-108. doi:10.1016/S0304-3959(03)00297-5. PubMed: 14581116.
36. Loggia ML, Mogil JS, Bushnell MC (2008) Experimentally induced mood changes preferentially affect pain unpleasantness. J Pain 9: 784-791. doi:10.1016/j.jpain.2008.03.014. PubMed: 18538637.
37. Nielsen J, Arendt-Nielsen L (1998) The importance of stimulus configuration for temporal summation of first and second pain to repeated heat stimuli. Eur J Pain 2: 329-341. doi:10.1016/S1090-3801(98)90031-3. PubMed: 10700328.
38. Granot M, Granovsky Y, Sprecher E, Nir RR, Yarnitsky D (2006) Contact heat-evoked temporal summation: tonic versus repetitivephasic stimulation. Pain 122: 295-305. doi:10.1016/j.pain.2006.02.003. PubMed: 16540248.
39. Soares BG, Fenton M, Chue P (2000) Sulpiride for schizophrenia. Cochrane Database Syst Rev: CD001162. doi:10.1002/14651858.CD001162. PubMed: 10796605
40. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1-24. doi:10.1016/0306-4522(91)90196-U. PubMed: 1676137.
41. Puech AJ, Simon P, Boissier JR (1978) Benzamides and classical neuroleptics: comparison of their actions using 6 apomorphine-induced effects. Eur J Pharmacol 50: 291-300. doi:10.1016/0014-2999(78)90134-6. PubMed: 29758.
42. Westerink BH, de Vries JB (1989) On the mechanism of neuroleptic induced increase in striatal dopamine release: brain dialysis provides direct evidence for mediation by autoreceptors localized on nerve terminals. Neurosci Lett 99: 197-202. doi:10.1016/0304-3940(89)90289-9. PubMed: 2526308.
43. Alfredsson G, Härnryd C, Wiesel FA (1984) Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacol (Berl) 84: 237-241. doi:10.1007/ BF00427452. PubMed: 6438683.
44. Mehta MA, Manes FF, Magnolfi G, Sahakian BJ, Robbins TW (2004) Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology 176: 331-342. doi:10.1007/s00213-004-1899-2. PubMed: 15114435.
45. Mehta MA, Montgomery AJ, Kitamura Y, Grasby PM (2008) Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology 196: 157-165. doi:10.1007/s00213-007-0947-0. PubMed: 17912501.
46. Tomori L, Vereczkey L, Past T, Singer J, Mészáros S (1992) In vivo bioequivalence study of Sulpirid (GYKI-Alkaloida) and Dogmatil fort (Delagrange) 200 mg sulpiride tablets in healthy volunteers. Acta Pharm Hung 62: 39-46. PubMed: 1566638.
47. McClelland GR, Cooper SM, Pilgrim AJ (1990) A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers. Br J Clin Pharmacol 30: 795-803. doi:10.1111/j.1365-2125.1990. tb05444.x. PubMed: 2288826.
48. Olejnik S, Algina J (2003) Generalized eta and omega squared statistics: measures of effect size for some common research designs. Psychol Methods 8: 434-447. doi:10.1037/1082-989X.8.4.434. PubMed: 14664681.
49. Cohen J (1992) A power primer. Psychol Bull 112: 155-159. doi:10.1037/0033-2909.112.1.155. PubMed: 19565683.
50. Olejnik S, Algina J (2000) Measures of Effect Size for Comparative Studies: Applications, Interpretations, and Limitations. Contemp Educ Psychol 25: 241-286. doi:10.1006/ceps.2000.1040. PubMed: 10873373.
51. Ferguson CJ (2009) An Effect Size Primer: A Guide for Clinicians and Researchers. Prof Psychol Res Pract 40: 532-538. doi:10.1037/A0015808.
52. Benfenati F, Bernardi P, Cortelli P, Capelli M, Adani C et al. (1981) Possible mixed agonist - antagonist activity of D-sulpiride at dopamine receptor level in man. Neurosci Lett 26: 289-295. doi:10.1016/0304-3940(81)90147-6. PubMed: 7033836.
53. Smit AJ, Meijer S, Wesseling H, Donker AJ, Reitsma WD (1990) Dissociation of renal vasodilator and natriuretic effects of dopamine during sulpiride infusion in normal man. Eur J Clin Pharmacol 39: 221-226. doi:10.1007/ BF00315100. PubMed: 2257856.
54. Horn PT, Kohli JD, Goldberg LI (1982) Effects of dopamine, NN-di-n-propyl dopamine, and (R)-and (S)-sulpiride on guinea pig blood pressure. J Cardiovasc Pharmacol 4(4): 668-675. doi:10.1097/00005344-198207000-00020. PubMed: 6181343.
55. Coull JT, Hwang HJ, Leyton M, Dagher A (2012) Dopamine precursor depletion impairs timing in healthy volunteers by attenuating activity in putamen and supplementary motor area. J Neurosci 32: 16704-16715. doi:10.1523/JNEUROSCI.1258-12.2012. PubMed: 23175824.
56. Vrshek-Schallhorn S, Wahlstrom D, White T, Luciana M (2013) The effect of acute tyrosine phenylalanine depletion on emotion-based decision-making in healthy adults. Pharmacol Biochem Behav 105: 51-57. doi:10.1016/j.pbb.2013.01. 013. PubMed: 23369984.
57. Leyton M, Young SN, Pihl RO, Etezadi S, Lauze C et al. (2000) Effects on mood of acute phenylalanine/tyrosine depletion in healthy women. Neuropsychopharmacology 22: 52-63. doi:10.1016/S0893-133X(99)00086-X. PubMed: 10633491.
58. Young SN, Smith SE, Pihl RO, Ervin FR (1985) Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology 87: 173-177. doi:10.1007/BF00431803. PubMed: 3931142.
59. McTavish SF, Cowen PJ, Sharp T (1999) Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. Psychopharmacology 141: 182-188. doi:10.1007/s002130050823. PubMed: 9952043.
60. McTavish SF, McPherson MH, Harmer CJ (2001) Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry 179: 356-360. doi:10.1192/bjp.179.4.356. PubMed: 11581118.
61. Leyton M, Dagher A, Boileau I, Casey K, Baker GB et al. (2004) Decreasing amphetamine-induced dopamine release by acute phenylalanine/tyrosine depletion: A PET/[11C]raclopride study in healthy men. Neuropsychopharmacology 29: 427-432. doi:10.1038/sj.npp.1300328. PubMed: 14583741.
62. Montgomery AJ, McTavish SFB, Cowen PJ, Grasby PM (2003) Reduction of brain dopamine concentration with dietary tyrosine plus phenylalanine depletion: an [11C]raclopride PET study. Am J Psychiatry 160: 1887-1889. doi:10.1176/appi.ajp.160.10.1887. PubMed: 14514507.
63. Fitzgerald P, Dinan TG (2008) Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22: 12-19. doi:10.1177/ 0269216307087148. PubMed: 18477617.
64. Lorr M, McNair DM, Fisher SU (1982) Evidence for bipolar mood states. J Pers Assess 46: 432-436. doi:10.1207/s15327752jpa4604-16. PubMed: 7120016.
65. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin J-A et al. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804. doi:10.1124/jpet.102.039867. PubMed: 12388666.
66. Price DD, Hu JW, Dubner R, Gracely RH (1977) Peripheral suppression of first pain and central summation of second pain evoked by noxious heat pulses. Pain 3: 57-68. doi:10.1016/0304-3959(77)90035-5. PubMed: 876667.
67. Schestatsky P, Kumru H, Valls-Solé J, Valldeoriola F, Marti MJ et al. (2007) Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 69: 2162-2169. doi:10.1212/01.wnl.0000295669.12443.d3. PubMed: 18056580.
68. Zambito Marsala S, Tinazzi M, Vitaliani R, Recchia S, Fabris F et al. (2011) Spontaneous pain, pain threshold, and pain tolerance in Parkinson's disease. J Neurol 258: 627-633. doi:10.1007/s00415-010-5812-0. PubMed: 21082324.
69. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I et al. (2005) Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 20: 1557-1563. doi:10.1002/mds.20629. PubMed: 16078219.
70. Dellapina E, Gerdelat-Mas A, Ory-Magne F, Pourcel L, Galitzky M et al. (2011) Apomorphine effect on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 26: 153-157. doi:10.1002/mds.23406. PubMed: 20960436.
71. Gierthmühlen J, Arning P, Binder A, Herzog J, Deuschl G et al. (2010) Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease. Mov Disord 25: 1195-1202. doi:10.1002/mds.23128. PubMed: 20629160.
72. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H (2003) Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 75: 77-82. doi:10.1016/S0165-0327(02)00025-3. PubMed: 12781354.
73. Wood PB, Patterson JC, Sunderland JJ, Tainter KH, Glabus MF, et al. (2007) Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 8: 51-58. doi:10.1016/j.jpain.2007.02.208. PubMed: 17023218.
74. Holman AJ, Myers RR (2005) A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52: 2495-2505. doi:10.1002/art.21191. PubMed: 16052595.
75. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sörensen J et al. (2000) Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 85: 483- 491. doi:10.1016/S0304-3959(99)00308-5. PubMed: 10781923.
76. Sörensen J, Bengtsson A, Bäckman E, Henriksson KG, Bengtsson M (1995) Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 24: 360-365. doi:10.3109/03009749509095181. PubMed: 8610220.
77. Sörensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L et al. (1997) Fibromyalgia - are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 24: 1615-1621. PubMed: 9263160.
78. Becker S, Schweinhardt P (2012) Dysfunctional Neurotransmitter Systems in Fibromyalgia, Their Role in Central Stress Circuitry and Pharmacological Actions on These Systems. Pain Res Treat 2012: 741746. PubMed: 22110944
79. Sommer C, Hauser W, Alten R, Petzke F, Spath M et al. (2012) [Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline]. Vol. 26. pp. 297-310 doi:10.1007/s00482-012-1172-2.
80. Brooks AM, Berns GS (2013) Aversive stimuli and loss in the mesocorticolimbic dopamine system. Trends Cogn Sci 17: 281-286. doi:10.1016/j.tics.2013.04.001. PubMed: 23623264.
81. Cabib S, Puglisi-Allegra S (2012) The mesoaccumbens dopamine in coping with stress. Neurosci Biobehav Rev 36: 79-89. doi:10.1016/j.neubiorev.2011.04. 012. PubMed: 21565217.
82. Peciña S, Cagniard B, Berridge KC, Aldridge JW, Zhuang X (2003) Hyperdopaminergic mutant mice have higher "wanting" but not "liking" for sweet rewards. J Neurosci 23: 9395-9402. PubMed: 14561867.
83. Wyvell CL, Berridge KC (2000) Intra-accumbens amphetamine increases the conditioned incentive salience of sucrose reward: enhancement of reward "wanting" without enhanced "liking" or response reinforcement. J Neurosci 20: 8122-8130. PubMed: 11050134.
84. Berridge KC (2007) The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 191: 391-431. doi:10.1007/s00213-006- 0578-x. PubMed: 17072591.
85. Girodo M, Wood D (1979) Talking yourself out of pain: the importance of believing that you can. Cognit Ther Res 3(1): 23-33. doi:10.1007/BF01172716.
86. Scott DJ, Heitzeg MM, Koeppe RA, Stohler CS, Zubieta JK (2006) Variations in the human pain stress experience mediated by ventral and dorsal basal ganglia dopamine activity. J Neurosci 26: 10789-10795. doi:10.1523/JNEUROSCI. 2577-06.2006. PubMed: 17050717.
87. Abercrombie ED, Keefe KA, DiFrischia DS, Zigmond MJ (1989) Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem 52: 1655-1658. doi:10.1111/j.1471-4159.1989. tb09224.x. PubMed: 2709017.
88. Kalivas PW, Duffy P (1995) Selective activation of dopamine transmission in the shell of the nucleus accumbens by stress. Brain Res 675: 325-328. doi:10.1016/0006-8993(95)00013-G. PubMed: 7796146.
89. Becker S, Gandhi W, Elfassy N, Schweinhardt P (in press) Dopamine enhances the effects of monetary reward and punishment on pain perception. Eur J Neurosci.
90. Carlsson A, Lindqvist M (1978) Dependence of 5-HT and catecholamine synthesis on concentrations of precursor amino-acids in rat brain. Naunyn Schmiedebergs Arch Pharmacol 303(2): 157-164. doi:10.1007/BF00508062. PubMed: 307698.
91. Fernstrom JD, Wurtman RJ, Hammarstrom-Wiklund B, Rand WM, Munro HN et al. (1979) Diurnal variations in plasma concentrations of tryptophan, tryosine, and other neutral amino acids: effect of dietary protein intake. Am J Clin Nutr 32: 1912-1922. PubMed: 573061.
92. Choi S, Disilvio B, Fernstrom MH, Fernstrom JD (2009) Meal ingestion, amino acids and brain neurotransmitters: effects of dietary protein source on serotonin and catecholamine synthesis rates. Physiol Behav 98: 156-162. doi:10.1016/j.physbeh.2009.05.004. PubMed: 19454292.
93. Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y (2012) Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain 153: 1193-1198. doi:10.1016/j.pain.2012.02.021. PubMed: 22480803.